The global canine arthritis treatment market is set to expand significantly over the next decade, according to the latest industry analysis. Estimated at USD 2.50 billion in 2024, the market is projected to grow at a compound annual growth rate (CAGR) of 4.20%, reaching USD 3.77 billion by 2034.
The rise in market size reflects a growing awareness and demand for effective arthritis treatments among pet owners worldwide. Factors contributing to this growth include increased availability of pet insurance covering arthritis care, enabling more comprehensive treatment options for dogs. Furthermore, the expansion of veterinary services offering specialized treatments such as acupuncture, hydrotherapy, and physical therapy has enhanced accessibility to high-quality care for arthritic dogs.
Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-3552
Increasing disposable income among pet owners has facilitated greater investment in advanced arthritis treatments. Canine arthritis treatments are also experiencing increasing demand from pet owners who own dogs affected by arthritis and seek treatments to improve their pets’ comfort and quality of life. This trend is also observed among pet insurance companies that provide coverage for veterinary expenses and help pet owners afford necessary care for their arthritic dogs.
Besides this, advancements in veterinary pharmaceuticals, such as new pain management medications and joint supplements, are providing more effective options for arthritis relief. This has resulted in a strong emphasis on improving the quality of life and mobility for arthritic dogs, driving demand for effective treatment options. Apart from this, minimally invasive surgical procedures for arthritis treatment are gaining popularity among pet owners due to their desire for less invasive yet effective solutions.
“There is still limited to no awareness about canine arthritis in the general population. Companies in the canine arthritis treatment market must leverage marketing efforts to raise awareness among both pet owners and veterinary professionals about the importance of early diagnosis and effective management of canine arthritis,” opines an FMI analyst.
Key Takeaways from the Market Study:
- The oral segment dominates the global canine arthritis treatment market with a share of 70% in 2024.
- On the basis of the drug class, the NSAIDs segment leads the canine arthritis treatment market with a share of 72% in 2024.
- The canine arthritis treatment market in India is anticipated to grow at a CAGR of 5.30% through 2034.
- The canine arthritis treatment market in Spain is estimated to rise at a 5.50% CAGR through 2034.
- The canine arthritis treatment market in Italy has the potential to increase at 4.90% CAGR through 2034.
- The Australian canine arthritis treatment market is predicted to rise by 4.70% CAGR through 2034.
- The canine arthritis treatment market in France is very likely to grow at a CAGR of 4.60% through 2034.
Ask for Customize Research Report: https://www.futuremarketinsights.com/customization-available/rep-gb-3552
Competitive Landscape:
- Canine arthritis treatment market is highly competitive, with several major companies and manufacturers investing heavily in research and development to innovate new medications, supplements, and therapeutic approaches.
- Some of the major companies in the market are Boehringer Ingelheim International GmbH., DAIICHI SANKYO COMPANY, LIMITED, Thorne, NUTRI-VET, American Regent, Inc., DSM, etc.
- Companies in the market are also expanding their distribution networks and partnerships with veterinary clinics, pet retailers, and online platforms to enhance their market reach and accessibility of their products to pet owners.
Recent Developments:
- In January 2023, TVM introduced DogStem, Europe’s first licensed stem cell therapy for canine osteoarthritis, which demonstrated efficacy in clinical trials.
- Elanco launched Galliprant in May 2019, a new treatment for canine osteoarthritis pain, which targets the EP4 receptor and reduces pain and inflammation.
- Rejuvenate Bio, in February 2024, partnered with a leading animal health company to develop groundbreaking gene therapy for canine osteoarthritis.
Key Companies in the Market:
- Boehringer Ingelheim International GmbH
- DAIICHI SANKYO COMPANY, LIMITED
- Thorne
- NUTRI-VET
- American Regent, Inc.
- DSM
- Zoetis
- National hog farmer
- Novasep
- Bayer AG
- Matsun Nutrition
A Full Report on Market: https://www.futuremarketinsights.com/checkout/3552
Canine arthritis treatment Market by Segmentation
By Treatment:
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Opioids
- Stem Cell Therapy
- Allogeneic Stem Cells
- Autologous Stem Cells
By Route of Administration:
- Oral Canine Arthritis Treatment
- Injectable Canine Arthritis Treatment
By Distribution Channel:
- Veterinary Hospitals & Clinics
- Retail Pharmacies
- Drug Stores
- e-Commerce
By Region:
- North America
- Latin America
- Asia Pacific
- Middle East and Africa (MEA)
- Europe
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube